Erasca Inc
Closed
18.86 3.12
Overview
Share price change
24h
Min
17.81
Max
19.07
Income | -154M -183M |
|---|---|
EPS | -0.6 |
Employees | 103 |
EBITDA | -151M -183M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +21.19% upside |
Next Earnings | 10 Aug 2026 |
|---|
Market Cap | 2.4B 5.7B |
|---|---|
Previous open | 15.74 |
Previous close | 18.86 |
Erasca Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Erasca Inc Forecast
Price Target
By TipRanks
21.19% upside
12 Months Forecast
Average 22.25 USD 21.19%
High 30 USD
Low 16 USD
Based on 8 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
